Vanda's resubmission was a complete response to the not approvable action letter that the company received on July 25, 2008.
The FDA has indicated that it has accepted the complete response for review and has set a new target action date of May 6, 2009.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index